Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Clin |
RCV000237247 | SCV005688661 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2023-11-07 | reviewed by expert panel | curation | NM_000527.5(LDLR):c.1747C>G (p.His583Asp) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying ACMG/AMP evidence codes PM2, PM5, PP3 and PS3_Supporting as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (specification version 1.2) on 7 November 2023. The supporting evidence is as follows: PM2: PopMax MAF = 0.000008790 (0.0008790%) in European (non-Finnish) (gnomAD v2.1.1). PP3: REVEL = 0.798. PM5: There is 1 variant in the same codon classified as Pathogenic by these guidelines, NM_000527.5(LDLR):c.1747C>T (p.His583Tyr) (ClinVar ID: 200921). PS3_Supporting: Functional studies (PMID 25647241, Thormaehlen et al., 2015) using HeLa-Kyoto cells, LDLR-GFP construct, WB and CLSM assays - results - most of mutant LDLR is in ER, LDLR activity decreased compared to WT - considered as disruptive. Therefore, PS3_Supporting is met. |
| LDLR- |
RCV000237247 | SCV000295632 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
| Dept. |
RCV000161999 | SCV000189574 | not provided | not provided | no assertion provided | in vitro |